Actively Recruiting
Rivaroxaban in Idiopathic Membranous Nephropathy
Led by Beijing Friendship Hospital · Updated on 2026-02-11
134
Participants Needed
1
Research Sites
155 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Through a prospective, single-center, randomized controlled trial, we aim to determine the thromboprophylactic efficacy of rivaroxaban in patients with idiopathic membranous nephropathy (IMN). IMN patients at high risk of thrombosis and low risk of bleeding will be enrolled and randomly assigned to a rivaroxaban group or a control group (receiving warfarin). Prophylactic anticoagulation will be administered with rivaroxaban or warfarin accordingly. Over the 6 months following initiation of prophylactic anticoagulation, the incidence of the primary efficacy endpoint (a composite of pulmonary embolism, deep vein thrombosis, and lower-extremity deep vein thrombosis) and the safety endpoint (bleeding events) will be compared between the two groups.
CONDITIONS
Official Title
Rivaroxaban in Idiopathic Membranous Nephropathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 80 years, either sex
- Kidney biopsy confirming idiopathic membranous nephropathy by light and electron microscopy
- High risk of thrombosis with nephrotic syndrome and serum albumin below 25 g/L
- Normal kidney function with normal creatinine clearance
You will not qualify if you...
- History of blood clots such as pulmonary embolism, renal vein thrombosis, or lower-extremity deep vein thrombosis
- Pulmonary diseases affecting ventilation-perfusion scan accuracy, including infection, inflammation, tumors, or COPD
- Inability to undergo ventilation-perfusion scanning due to cardiac shunts, allergies, or inability to cooperate
- Active significant bleeding
- Pregnancy or breastfeeding
- Recent heart attack, stroke, or presence of atrial fibrillation
- Active infection or active cancer
- Blood clotting disorders, liver dysfunction with aminotransferases 3 times above normal, or low platelet count below 100 x 10^9/L
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Friedship Hospital
Beijing, Beijing Municipality, China, 100050
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here